Health Immutep’s LAG-3 Drug Fails Phase 3 Study in Lung Cancer Immutep’s experimental drug targeting LAG-3 has failed to demonstrate efficacy in a Phase 3 clinical trial for lung cancer. The trial results, announced on... Editorial13 March, 2026